14 April, 2016
The Inserm UMR 1102 “Cancer Vaccines and Immune Regulation” in Nantes, France, invites applications from outstanding scientists to join the Unit and establish his/her own research program in the field of cancer immunology. Currently, the laboratory conducts research on the mechanisms involved in immune surveillance by helper/effector T cells and immune subversion by regulatory/immunosuppressive Treg. The laboratory is located in and is part of the Cancer Research ICO (Institut de Cancérologie de l’Ouest), and closely collaborates with the IMAD (L’Institut des Maladies de l’Appareil Digestif) at the CHU of Nantes. The close proximity of clinicians offers a highly stimulating and collaborative research environment for translational research. Applicants must hold a PhD or a MD/PhD degree, international academic experience in immunology and should show a track record of good scientific productivity. Experience with group supervision and management, and/or success in obtaining research funds and supervising other scientist or PhD students will be considered an asset. The appointment will be available in priority for researchers holding a permanent position at French Research Institutions such as Inserm or CNRS as well as to a researcher with a high potential of successfully competing for such a position. The successful candidates will have access to common laboratory space and to state-of-the art core facilities. In addition, depending on the quality of his/her track record, the successful candidate could benefit from an interface contract with ICO.
Applications, including a CV, a list of publications, a summary of scientific achievements, an outline of the proposed scientific project and contact information of referees should be sent to Raïssa du Fretay : firstname.lastname@example.org, copy to email@example.com
This post is not valid after Friday May 13th, 2016